866-997-4948(US-Canada Toll Free)

United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Report 2017

Published By :

QYResearch

Published Date : Feb 2017

Category :

Pharmaceutical

No. of Pages : 107 Pages

Notes:
Sales, means the sales volume of Non-alcoholic Fatty Liver Disease (NAFLD) Drug
Revenue, means the sales value of Non-alcoholic Fatty Liver Disease (NAFLD) Drug

This report studies sales (consumption) of Non-alcoholic Fatty Liver Disease (NAFLD) Drug in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering
Conatus Pharmaceuticals
Daewoong Pharmaceutical
Galmed International
Kyorin Pharmaceutical
Metabolic Solutions Development
Novartis AG
Phenex Pharmaceuticals
Raptor Pharmaceuticals
TCM Biotech International
Tobira Therapeutics
Verva Pharmaceuticals
Zafgen

Market Segment by States, covering
California
Texas
New York
Florida
Illinois
Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into
Type I
Type II
Split by applications, this report focuses on sales, market share and growth rate of Non-alcoholic Fatty Liver Disease (NAFLD) Drug in each application, can be divided into
Application 1
Application 2

Table of Contents

United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Report 2017
1 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Overview
1.1 Product Overview and Scope of Non-alcoholic Fatty Liver Disease (NAFLD) Drug
1.2 Classification of Non-alcoholic Fatty Liver Disease (NAFLD) Drug
1.2.1 Type I
1.2.2 Type II
1.3 Application of Non-alcoholic Fatty Liver Disease (NAFLD) Drug
1.3.1 Application 1
1.3.2 Application 2
1.4 United States Market Size Sales (Volume) and Revenue (Value) of Non-alcoholic Fatty Liver Disease (NAFLD) Drug (2012-2022)
1.4.1 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Growth Rate (2012-2022)
1.4.2 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate (2012-2022)

2 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Competition by Manufacturers
2.1 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share of Key Manufacturers (2015 and 2016)
2.2 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Share by Manufactures (2015 and 2016)
2.3 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Average Price by Manufactures (2015 and 2016)
2.4 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Competitive Situation and Trends
2.4.1 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Concentration Rate
2.4.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share of Top 3 and Top 5 Manufacturers
2.4.3 Mergers & Acquisitions, Expansion

3 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales (Volume) and Revenue (Value) by States (2012-2017)
3.1 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by States (2012-2017)
3.2 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Market Share by States (2012-2017)
3.3 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Price by States (2012-2017)

4 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales (Volume) and Revenue (Value) by Type (2012-2017)
4.1 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by Type (2012-2017)
4.2 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Market Share by Type (2012-2017)
4.3 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Price by Type (2012-2017)
4.4 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Growth Rate by Type (2012-2017)

5 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales (Volume) by Application (2012-2017)
5.1 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Market Share by Application (2012-2017)
5.2 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Manufacturers Profiles/Analysis
6.1 Conatus Pharmaceuticals
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product Type, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 Conatus Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.1.4 Main Business/Business Overview
6.2 Daewoong Pharmaceutical
6.2.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product Type, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 Daewoong Pharmaceutical Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.2.4 Main Business/Business Overview
6.3 Galmed International
6.3.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product Type, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 Galmed International Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.3.4 Main Business/Business Overview
6.4 Kyorin Pharmaceutical
6.4.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product Type, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 Kyorin Pharmaceutical Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.4.4 Main Business/Business Overview
6.5 Metabolic Solutions Development
6.5.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product Type, Application and Specification
6.5.2.1 Product A
6.5.2.2 Product B
6.5.3 Metabolic Solutions Development Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.5.4 Main Business/Business Overview
6.6 Novartis AG
6.6.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product Type, Application and Specification
6.6.2.1 Product A
6.6.2.2 Product B
6.6.3 Novartis AG Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.6.4 Main Business/Business Overview
6.7 Phenex Pharmaceuticals
6.7.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product Type, Application and Specification
6.7.2.1 Product A
6.7.2.2 Product B
6.7.3 Phenex Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.7.4 Main Business/Business Overview
6.8 Raptor Pharmaceuticals
6.8.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product Type, Application and Specification
6.8.2.1 Product A
6.8.2.2 Product B
6.8.3 Raptor Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.8.4 Main Business/Business Overview
6.9 TCM Biotech International
6.9.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product Type, Application and Specification
6.9.2.1 Product A
6.9.2.2 Product B
6.9.3 TCM Biotech International Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.9.4 Main Business/Business Overview
6.10 Tobira Therapeutics
6.10.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Product Type, Application and Specification
6.10.2.1 Product A
6.10.2.2 Product B
6.10.3 Tobira Therapeutics Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
6.10.4 Main Business/Business Overview
6.11 Verva Pharmaceuticals
6.12 Zafgen

7 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Manufacturing Cost Analysis
7.1 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Non-alcoholic Fatty Liver Disease (NAFLD) Drug

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Non-alcoholic Fatty Liver Disease (NAFLD) Drug Major Manufacturers in 2015
8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List

10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Forecast (2017-2022)
11.1 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue Forecast (2017-2022)
11.2 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Forecast by Type (2017-2022)
11.3 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Forecast by Application (2017-2022)
11.4 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Price Forecast (2017-2022)

12 Research Findings and Conclusion

13 Appendix
Methodology
Analyst Introduction
Data Source

List of Table

List of Tables and Figures

Figure Picture of Non-alcoholic Fatty Liver Disease (NAFLD) Drug
Table Classification of Non-alcoholic Fatty Liver Disease (NAFLD) Drug
Figure United States Sales Market Share of Non-alcoholic Fatty Liver Disease (NAFLD) Drug by Type in 2015
Table Application of Non-alcoholic Fatty Liver Disease (NAFLD) Drug
Figure United States Sales Market Share of Non-alcoholic Fatty Liver Disease (NAFLD) Drug by Application in 2015
Figure United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Growth Rate (2012-2022)
Figure United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate (2012-2022)
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales of Key Manufacturers (2015 and 2016)
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Share by Manufacturers (2015 and 2016)
Figure 2015 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Share by Manufacturers
Figure 2016 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Share by Manufacturers
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue by Manufacturers (2015 and 2016)
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue Share by Manufacturers (2015 and 2016)
Table 2015 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue Share by Manufacturers
Table 2016 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue Share by Manufacturers
Table United States Market Non-alcoholic Fatty Liver Disease (NAFLD) Drug Average Price of Key Manufacturers (2015 and 2016)
Figure United States Market Non-alcoholic Fatty Liver Disease (NAFLD) Drug Average Price of Key Manufacturers in 2015
Figure Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share of Top 3 Manufacturers
Figure Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share of Top 5 Manufacturers
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales by States (2012-2017)
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Share by States (2012-2017)
Figure United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Share by States in 2015
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Market Share by States (2012-2017)
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue Share by States (2012-2017)
Figure Revenue Market Share of Non-alcoholic Fatty Liver Disease (NAFLD) Drug by States (2012-2017)
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Price by States (2012-2017)
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales by Type (2012-2017)
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Share by Type (2012-2017)
Figure United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Share by Type in 2015
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Market Share by Type (2012-2017)
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Non-alcoholic Fatty Liver Disease (NAFLD) Drug by Type (2012-2017)
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Price by Type (2012-2017)
Figure United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Growth Rate by Type (2012-2017)
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales by Application (2012-2017)
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Share by Application (2012-2017)
Figure United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Share by Application in 2015
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Growth Rate by Application (2012-2017)
Figure United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Growth Rate by Application (2012-2017)
Table Conatus Pharmaceuticals Basic Information List
Table Conatus Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
Figure Conatus Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Share (2012-2017)
Table Daewoong Pharmaceutical Basic Information List
Table Daewoong Pharmaceutical Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
Table Daewoong Pharmaceutical Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Share (2012-2017)
Table Galmed International Basic Information List
Table Galmed International Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
Table Galmed International Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Share (2012-2017)
Table Kyorin Pharmaceutical Basic Information List
Table Kyorin Pharmaceutical Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
Table Kyorin Pharmaceutical Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Share (2012-2017)
Table Metabolic Solutions Development Basic Information List
Table Metabolic Solutions Development Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
Table Metabolic Solutions Development Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Share (2012-2017)
Table Novartis AG Basic Information List
Table Novartis AG Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
Table Novartis AG Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Share (2012-2017)
Table Phenex Pharmaceuticals Basic Information List
Table Phenex Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
Table Phenex Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Share (2012-2017)
Table Raptor Pharmaceuticals Basic Information List
Table Raptor Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
Table Raptor Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Share (2012-2017)
Table TCM Biotech International Basic Information List
Table TCM Biotech International Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
Table TCM Biotech International Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Share (2012-2017)
Table Tobira Therapeutics Basic Information List
Table Tobira Therapeutics Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
Table Tobira Therapeutics Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Share (2012-2017)
Table Verva Pharmaceuticals Basic Information List
Table Zafgen Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Non-alcoholic Fatty Liver Disease (NAFLD) Drug
Figure Manufacturing Process Analysis of Non-alcoholic Fatty Liver Disease (NAFLD) Drug
Figure Non-alcoholic Fatty Liver Disease (NAFLD) Drug Industrial Chain Analysis
Table Raw Materials Sources of Non-alcoholic Fatty Liver Disease (NAFLD) Drug Major Manufacturers in 2015
Table Major Buyers of Non-alcoholic Fatty Liver Disease (NAFLD) Drug
Table Distributors/Traders List
Figure United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production and Growth Rate Forecast (2017-2022)
Figure United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate Forecast (2017-2022)
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production Forecast by Type (2017-2022)
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption Forecast by Application (2017-2022)
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Forecast by States (2017-2022)
Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Share Forecast by States (2017-2022)

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *